WASHINGTON, April 26 – The Pharmaceuticalโข research adn Manufacturersโฃ of America (PhRMA), the leading U.S. lobby group for drugmakers, announced plans today too launch a website aimed at โขconnecting patients with resourcesโฃ for cheaper prescriptionโ drugs, including manufacturer assistance programsโ and discountโ cards. the initiative comes as high drug prices remain a significant concernโ for Americans andโ a key political issue heading into the 2024 election cycle.
The website,expected to launch in the โcoming weeks,will serve as a centralized hub for patients seeking financialโ aid to afford their medications. โขphrma says the platform will aggregate information onโฃ programs offered by its member companies, as โwellโข as links to other resources like state and federal assistance programs and non-profitโค organizations. This move represents aโ shift for the industry group, frequently enough criticized forโฃ opposing policiesโฃ aimed at lowering drug costs, and seeks to address affordability concerns directly with patients.”We recognize the financial โburden that prescription medicines can pose forโข some patients, and we want to ensureโค they have access to the resources available to help โขthem afford their medications,” said a PhRMA spokesperson. “This โwebsite is โฃa step towards greater transparency and accessibility.”
The launchโค follows increasedโค scrutinyโ from lawmakers and the Biden administration regardingโข drug pricing practices. The Inflation โReduction Act, signed into law last โyear, allows Medicare to negotiateโฃ prices โfor some high-cost drugs, a move PhRMA strongly opposed.while the website won’t directly address the impact of โthe Inflation Reduction Act, it arrives amid ongoing debate โover drug affordability and access.
PhRMA’s member companies include major pharmaceutical giantsโ like Pfizer, Johnson & Johnson, andโข Merck. The group spendsโ tens of millions of dollars annually on lobbying efforts toโ influence drug policy. The new website is โintended to showcase a more patient-focused approach, though critics remain skeptical about the industry’s commitment to broader affordabilityโฃ solutions.